Archived Facts

Pfizer said Wednesday it entered a licensing agreement with Puma Biotechnology for the development and marketing of neratinib, an experimental drug that has shown promise in treating a subset of breast cancer patients.

Popular Posts:

Related Posts:

Leave a Reply